Briefly noted: MA Lowry et al. JPGN 2018; 67: 198-203. This study showed that active eosinophilic esophagitis (EoE) was associated with much lower impedance values that inactive EoE, NERD, and controls. At 2, 5 and 10 cm above the squamo-columnar junction, median values of impedance with active EoE were 1069, 1368, and 1707 respectively. In comparison, inactive EoE had median values were 3663, 3657, and 4494, respectively. My take: Since impedance was also performed during endoscopy with sedation, this does not represent a significant advance in current management.
A prospective pediatric eosinophilic esophagitis (EoE) study (C Gutierrez-Junquera et al. JPGN 2018; 67: 210-6) examines the use of proton pump inhibitors (PPIs) for long-term management for this disorder.
After diagnosis of EoE, children received esomeproazole (1 mg/kg/dose BID). For those with a response (<15 eos/hpf), they were maintained on 1 mg/kg/day for one year.
- Of the initial cohort of 109, 72 (66%) had response to esomeprazole.
- 57 of these responders were subsequently followed in this study. At the lower daily esomeprazole dose, 70.1% (n=40) continued with <15 eos/hpf and 29.9% (n=17) had relapse.
- Maintaining response was more common among those who achieved an initial response (with BID esomeprazole) of <5 eos/hpf compared to those who had achieved an initial response of 6-14 eos/hpf. At 1 year, in those with who had a more complete response, 81% maintained eosinophil count <15/hpf compared with only 50% in those with a lesser initial response.
- Adverse events with prolonged treatment were uncommon and included self-resolving diarrhea in three, headache in one and urticaria in one; the latter two adverse effects responded to change to lansoprazole
- PPI treatment is effective in probably 40-50% of individuals with EoE (though higher response in this study)
- Some individuals need higher doses of PPIs
- Due to the high response rate, this underscores the need to diagnose EoE prior to using PPIs or after they have been discontinued.
Related blog posts:
- Do we still need PPI-REE?
- Nexium versus Fluticasone for EoE
- Guidelines for Eosinophilic Esophagitis
- Higher Doses of Topical Steroids for Eosinophilic Esophagitis …
- Putting in Place a Big Piece of the Eosinophilic Esophagitis …
- Eosinophilic Esophagitis Slide Set | gutsandgrowth
- MicroRNA signature for eosinophilic esophagitis | gutsandgrowth
Patient Educational Video (~2 min) from Cincinnati Children’s: What is Eosinophilic Esophagitis?
T Shoda et al. The Lancet Gastroenterology & Hepatology, published online May 2, 2018. DOI: https://doi.org/10.1016/S2468-1253(18)30096-7
Eosinophilic oesophagitis is understood in terms of quantifiable histological, endoscopic, and molecular features. Data are scant for inter-relations of these features and their potential to identify distinct disease endotypes. We aimed to identify clinical–pathological correlations between endoscopic and histological disease variables by transcription profiling of the oesophagus of patients with eosinophilic oesophagitis of varying severity and disease activity states.
We did a cross-sectional study across ten hospital sites in the USA associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers. We analysed oesophageal biopsy specimens taken from paediatric and adult patients with eosinophilic oesophagitis (discovery cohort), using the eosinophilic oesophagitis diagnostic panel (EDP), a set of 96 informative transcripts. Histological and endoscopic features were assessed by quantification of oesophageal eosinophils and use of the eosinophilic oesophagitis histology scoring system (HSS) and the eosinophilic oesophagitis endoscopic reference score (EREFS). Associations among the various histological, endoscopic, and molecular features were analysed by Spearman correlation. Results were replicated in a biologically independent, single-centre, validation cohort of patients with active eosinophilic oesophagitis.
The discovery cohort contained 185 samples and the validation cohort comprised 100 specimens. In the discovery cohort, EDP showed intersite consistency, significant correlation with oesophageal eosinophils (p<0·0001), and similar findings between paediatric and adult patients. Of eight HSS domains, basal zone hyperplasia correlated with the EDP (median Spearman ρ 0·47 [IQR 0·36–0·60]). Of five EREFS features, distal furrows correlated with the EDP (median Spearman ρ 0·42 [0·32–0·50]). By analysing active eosinophilic oesophagitis in the discovery cohort, the EDP identified three clusters associated with distinct endotypes (termed EoEe1–3) despite similar eosinophil levels. EoEe1 was associated with a normal-appearing oesophagus (risk ratio [RR] 3·27, 95% CI 1·04–10·27; p=0·0443), an inverse association with a history of oesophageal dilation (0·27, 0·09–0·82; p=0·0105) and showed relatively mild histological, endoscopic, and molecular changes. EoEe2 showed an inflammatory and steroid-refractory phenotype (RR 2·77, 95% CI 1·11–6·95; p=0·0376) and had the highest expression of inflammatory cytokines and steroid-responding genes. EoEe3 was associated with a narrow-calibre oesophagus (RR 7·98, 95% CI 1·84–34·64; p=0·0013) and adult onset (2·22, 1·19–4·12; p=0·0155), and showed the highest degree of endoscopic and histological severity and the lowest expression of epithelial differentiation genes. These endotypes were replicated in the validation cohort by clustering and with an eosinophilic oesophagitis endotype-prediction algorithm.
Our new disease classification stratifies patients with eosinophilic oesophagitis into subgroups with potential clinical and therapeutic significance and provides a framework for a precision medicine approach to eosinophilic oesophagitis.
Related blog entries:
Gastroenterology published a ‘special issue’ in January 2018 (volume 154; pages 263-451) which reviewed several esophageal diseases in-depth: gastroesophageal reflux disease (GERD), eosinophilic esophagitis (EoE), and esophageal cancer. For me, this issue served as a good review on GERD and EoE.
A couple of items that I picked up:
- For both GERD and functional dyspepsia, “estimated prevalence values are approximately 20% for each.” (pg 269)
- “15% of healthy individuals may have microscopic esophagitis” (pg 291)
- For pH-impedance, the current view of non-acid reflux is unchanged: “unknown clinical relevance of non-acid reflux in the setting of aggressive acid suppression.” (pg 291)
- Treatment algorithm for EoE (pg 353):
- Induction treatment with any of the three approaches: high dose topical corticosteroids, double dose proton pump inhibitor (PPI) or elimination diet “because no comparative studies have shown any of these to be superior to the others.”
- Then, re-evaluation after 2-3 months (clinical, endoscopic, and histologic). Responders should continue on therapy but maintenance treatment suggests low dose topical corticosteroid, lowering PPI to single dose, or continuing elimination diet. For nonresponders, switching to one of the other two treatment approaches is recommended.
- The algorithm indicates that followup evaluation of responders to insure ongoing response should be considered 1 year later
- As for dilatation, the authors note that this does not control the underlying inflammation and thus should not be used as monotherapy. Also, “after dilatation, 75% of patients have considerable chest pain that may last several days.” (pg 354)
Unrelated twitter post below -IgG allergy testing is NOT a good idea:
This link for the NASPGHAN abstracts :NASPGHAN 2017 Scientific Abstracts
The following slides are from some of the abstract posters. This first poster (next 5 pics) showed that symptom association with meals is not predictive of aspiration among a selected group of children who underwent swallow study evaluations. In the figures, the blue bars are children who passed the swallow study whereas the red bars indicate the children who failed the swallow study.
This next slide demonstrated that a six food diet for EoE could be administered blenderized via a gastrostomy tube.
The next slide showed that irritable bowel syndrome was more frequent (overall hazard ratio of 1.52) following a urinary tract infection in the first year of life.
The next pictures are from a poster discussing high rates of recurrent C difficile infection following fecal microbial transplantation in pediatric patients with inflammatory bowel disease (mainly ulcerative colitis). An inference from this study would be that many cases of C difficile that were attributed as causing symptoms could in fact have been from a flare up of their IBD. More details about the diagnosis of C difficile (based on PCR or ELISA) would be helpful
The next poster provides data from CHOP experience with Ustekinumab. Overall, in this highly-selected (refrcactory) population the long term improvement was low; while one-third had steroid-free remission at week 8, this was not maintained at week 16 and week 24. In addition, among the 22 patients, one developed transverse myelitis.
This study that follows (next two pics) documented the relative safety of liver biopsies (mainly percutaneous without interventional radiology) in the post-transplant period. The two most serious adverse events, cholangitis and bile leak, helped identify biliary strictures.
The following collaborative study examined the neurocognitive status of children with Alagille syndrome. Overall, this study shows that children with Alagille syndrome are at increased risk of low IQ compared to children with other cholestatic diseases.
This blog entry has abbreviated/summarized this presentation. Though not intentional, some important material is likely to have been omitted; in addition, transcription errors are possible as well.
This first slide shows the growth in NASPGHAN membership:
Year in Review
Melvin Heyman Editor, JPGN
This lecture reviewed a number of influential studies that have been published in the past year. After brief review of the study, Dr. Heyman summarized the key take-home point.